Antti Kontturi1,2, Hanna Soini3, Jukka Ollgren3, Eeva Salo4. 1. Doctoral Programme in Population Health, University of Helsinki, Finland. 2. Children's Hospital, Pediatric Research Center, University of Helsinki and Helsinki University Hospital, Finland. 3. Department of Health Security, National Institute for Health and Welfare, Finland. 4. Department of Pediatric Infectious Diseases, Children's Hospital, University of Helsinki and Helsinki University Hospital, Finland.
Abstract
Background: Epidemiological data on childhood nontuberculous mycobacterial (NTM) disease is scarce and the protective effect of bacille Calmette-Guérin (BCG) vaccination remains debated. In 2006, the BCG policy in Finland changed from universal to selective. We aimed to study the effect of the BCG coverage decrease on the incidence of childhood NTM infections in Finland. Methods: We conducted a nationwide, population-based, retrospective study of NTM notifications recorded to the National Infectious Diseases Register between 1995 and 2016 and identified native-born children aged 0-4 years infected with NTM. Poisson log-linear model was used to estimate the change in the incidence rate of cohorts born during universal or selective BCG policy between 1995 and 2015. Results: We identified 97 native-born children aged <5 years infected with NTM (median age, 27 months; female-to-male ratio, 2:1). The most common species was Mycobacterium avium (n = 69 [71%]). The estimated incidence rates of NTM in universal-BCG and selective-BCG cohorts were 0.2 and 3.9 per 100000 person-years, respectively. The incidence rate ratio of selective-BCG cohorts compared to universal-BCG cohorts was 19.03 (95% confidence interval, 8.82-41.07; P < .001). Conclusions: After infant BCG coverage in Finland decreased, childhood NTM infections increased drastically. As there is no other apparent cause for the increase, this indicates that BCG offers protection against childhood NTM disease. This observation adds to the understanding of childhood NTM epidemiology and might explain why the disease is emerging in some countries.
Background: Epidemiological data on childhood nontuberculous mycobacterial (NTM) disease is scarce and the protective effect of bacille Calmette-Guérin (BCG) vaccination remains debated. In 2006, the BCG policy in Finland changed from universal to selective. We aimed to study the effect of the BCG coverage decrease on the incidence of childhood NTM infections in Finland. Methods: We conducted a nationwide, population-based, retrospective study of NTM notifications recorded to the National Infectious Diseases Register between 1995 and 2016 and identified native-born children aged 0-4 years infected with NTM. Poisson log-linear model was used to estimate the change in the incidence rate of cohorts born during universal or selective BCG policy between 1995 and 2015. Results: We identified 97 native-born children aged <5 years infected with NTM (median age, 27 months; female-to-male ratio, 2:1). The most common species was Mycobacterium avium (n = 69 [71%]). The estimated incidence rates of NTM in universal-BCG and selective-BCG cohorts were 0.2 and 3.9 per 100000 person-years, respectively. The incidence rate ratio of selective-BCG cohorts compared to universal-BCG cohorts was 19.03 (95% confidence interval, 8.82-41.07; P < .001). Conclusions: After infant BCG coverage in Finland decreased, childhood NTM infections increased drastically. As there is no other apparent cause for the increase, this indicates that BCG offers protection against childhood NTM disease. This observation adds to the understanding of childhood NTM epidemiology and might explain why the disease is emerging in some countries.
Authors: Shelby Daniel-Wayman; Getahun Abate; Daniel L Barber; Luiz E Bermudez; Rhea N Coler; Michael H Cynamon; Charles L Daley; Rebecca M Davidson; Thomas Dick; R Andres Floto; Emily Henkle; Steven M Holland; Mary Jackson; Richard E Lee; Eric L Nuermberger; Kenneth N Olivier; Diane J Ordway; D Rebecca Prevots; James C Sacchettini; Max Salfinger; Christopher M Sassetti; Christine F Sizemore; Kevin L Winthrop; Adrian M Zelazny Journal: Am J Respir Crit Care Med Date: 2019-04-15 Impact factor: 21.405
Authors: Srabanti Rakshit; Asma Ahmed; Vasista Adiga; Bharath K Sundararaj; Pravat Nalini Sahoo; John Kenneth; George D'Souza; Wesley Bonam; Christina Johnson; Kees Lmc Franken; Tom Hm Ottenhoff; Greg Finak; Raphael Gottardo; Kenneth D Stuart; Stephen C De Rosa; M Juliana McElrath; Annapurna Vyakarnam Journal: JCI Insight Date: 2019-12-19
Authors: Tiffany A Claeys; Oscar Rosas Mejia; Samuel Marshall; Jason A Jarzembowski; Don Hayes; Natalie M Hull; Namal P M Liyanage; Robert H Chun; Cecille G Sulman; Anna R Huppler; Richard T Robinson Journal: J Infect Dis Date: 2019-10-22 Impact factor: 5.226
Authors: Nakwon Kwak; Ha Won Hwang; Hyung-Jun Kim; Hyun Woo Lee; Jae-Joon Yim; Chang-Hoon Lee Journal: J Korean Med Sci Date: 2022-07-04 Impact factor: 5.354
Authors: Seul Gi Park; Hyojin Kim; Jin Ho Paik; Kyoung Un Park; Jeong Su Park; Woo Jin Jeong; Young Ho Jung; Jung Im Na; Ki Hyuk Sung; Ji Young Kim; Heeyoung Lee; Hyunju Lee Journal: J Korean Med Sci Date: 2019-12-02 Impact factor: 2.153
Authors: Ida Marie Hoel; Lisbet Sviland; Heidi Syre; Anne Ma Dyrhol-Riise; Ingerid Skarstein; Peter Jebsen; Melissa Davidsen Jørstad; Harald Wiker; Tehmina Mustafa Journal: BMC Infect Dis Date: 2020-02-12 Impact factor: 3.090
Authors: Champa N Ratnatunga; Viviana P Lutzky; Andreas Kupz; Denise L Doolan; David W Reid; Matthew Field; Scott C Bell; Rachel M Thomson; John J Miles Journal: Front Immunol Date: 2020-03-03 Impact factor: 7.561